FIG 1.
Antiviral activity of miglustat (N-butyl-1-deoxynojirimycin) and UV-4 [N-(9-methoxynonyl)-1-deoxynojirimycin] against HM175/18f-NLuc virus in Huh-7.5 cells. (A) Organization of the reporter virus genome showing the insertion of the nanoluciferase (NLuc) sequence between VP1pX and 2B, where it is flanked by 3Cpro cleavage sites. IRES, internal ribosome entry site; RdRp, RNA-dependent RNA polymerase. (B) Percent inhibition of NLuc activity expressed by HM175/18f-NLuc virus in cells treated with increasing concentrations of iminosugar compounds. Cells were treated for 72 h prior to infection with naked, nonenveloped virus and harvested for NLuc assays at 12 h p.i. Data shown are means ± standard deviations (SD) from 3 technical replicates fit to a variable-slope (four-parameter) nonlinear regression model. The estimated IC50s were 32.13 μM (95% confidence interval, 27.75 to 37.21 μM) for miglustat and 8.045 μM (95% confidence interval, 6.410 to 10.10 μM) for UV-4.